Oral Insulin Finally Realized: Some Are Calling It a Disruptive Technology, But Could It Be The Long Awaited "Holy Grail" of Drug Delivery?

Share Article

A major breakthrough in the quest for oral insulin was announced by Dr. Daniel DeBrouse, CEO, CSO of Tamarisk Technologies of Meeker, OK. This comes just days after his publishing of nearly a decade of research in oral drug delivery. Tamarisk Technologies is already in licensing talks with several big pharmas.

News Image
“We all know the "holy grail" of drug delivery is insulin. If you can deliver that orally you can pretty much deliver anything.”

"The data doesn't lie," said Dr DeBrouse. "After years of research, I am happy to say, not only have we achieved our goal of providing the world with the first clinically relevant oral formulation of insulin, but we have developed a Serum-Specific broad spectrum transport vehicle capable of reproducibly transporting and dosing the bloodstream with nearly 92% of any number of complex therapeutic peptides."

“We all know the "holy grail" of drug delivery is insulin. If you can deliver that orally you can pretty much deliver anything.”

Millions of patients worldwide require Insulin treatment, therefore a successful oral Insulin formulation has long been sought after to eliminate the use of needles, as well as the trauma associated with the use of Insulin injections. Though there have been many attempts to do so, until now, a viable oral alternative capable of delivering a therapeutic dose of insulin has yet to be confirmed.

This novel Oral Insulin research initiative of Tamarisk Technologies is said to have surrendered, not only the successful oral administration of Insulin, but the clinical trials reflected on http://www.tamarisktechnologies.com also confirm the nano-encapsulated Peptide YY 3-36, EPO, Tumor Necrosis Factor, and Pegylated Interferon within their patented SSNe Vehicle. A number of other biologically active molecules reportedly have demonstrated an absolute bioavailability of nearly 92% with a Cmax, in each case, occurring one hour after administration.

Dr DeBrouse continued by stating, “This formulation may have taken years, but once identified I ended up with a vehicle 100% resistant to gastro intestinal fluids. It is completely protected during the gestational process. The process of manufacturing of the nano-encapsulation is actually very simple and is relatively an inexpensive process.”

Tamarisk Technologies is a scientific research and development company with corporate offices based in Las Vegas, NV. For more information on Tamarisk's Serum Specific Oral drug delivery and other novel technologies, visit http://www.tamarisktechnologies.com or contact Christopher LaPoma, VP Operations/Business Development, at licensing(at)tamarisktech(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Christopher LaPoma

Email >